• Yuhao Zhang, Xiuchao Geng, Yanli Tan, Qiang Li, Can Xu, Jianglong Xu, Liangchao Hao, Zhaomu Zeng, Xianpu Luo, Fulin Liu, and Hong Wang.
• School of Medicine, Hebei University, Baoding, 071000, China.
• Biomed. Pharmacother. 2020 Jul 1; 127: 110195.

AbstractSince early December 2019, a number of pneumonia cases associated with unknown coronavirus infection were identified in Wuhan, China, and many additional cases were identified in other regions of China and in other countries within 3 months. Currently, more than 80,000 cases have been diagnosed in China, including more than 3000 deaths. The epidemic is spreading to the rest of the world, posing a grave challenge to prevention and control. On February 12, 2020, the International Committee on Taxonomy of Viruses and the World Health Organization officially named the novel coronavirus and associated pneumonia as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19), respectively. According to the recent research on SARS-CoV-2, the virus mainly infects the respiratory system but may cause damage to other systems. In this paper, we will systematically review the pathogenic features, transmission routes, and infection mechanisms of SARS-CoV-2, as well as any adverse effects on the digestive system, urogenital system, central nervous system, and circulatory system, in order to provide a theoretical and clinical basis for the diagnosis, classification, treatment, and prognosis assessment of SARS-CoV-2 infection.Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

31 keywords...

hide…